Company: MDCXW
Filing Date: 2025-05-30
Form Type: 424B4
Source: 0001062993-25-010548
Chunk: 4

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-30
Form: 424B4
Chunk 4
---
, and period end indicative rates of exchange for $1.00 expressed in Canadian dollars as published by the Bank of Canada:

|                             |   Period ended 
 March 31, 2025 
           (C$) |        Year ended 
 December 31, 2024 
              (C$) |        Year ended 
 December 31, 2023 
              (C$) |
|:----------------------------|---------------:|------------------:|------------------:|
| As at end of period         |         1.4376 |            1.4389 |            1.3226 |
| Low for the period          |         1.4166 |            1.3316 |            1.3128 |
| High for the period         |         1.4603 |            1.4416 |            1.3875 |
| Average rate for the period |         1.4352 |            1.3698 |            1.3497 |

On May 29, 2025, the daily average exchange rate for Canadian dollars in terms of the U.S. dollar, as quoted by the Bank of Canada, was $1.00 = C$1.3806.

<div align='center'>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</div>

This prospectus includes forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this prospectus regarding our strategy, future operations, regulatory process, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. The words "believe", "anticipate", "intend", "expect", "target", "goal", "estimate", "plan", "assume", "may", "will", "predict", "project", "would", "could" and similar expressions or the negative of such terms are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

The forward-looking statements in this prospectus include, but are not limited to, statements about:

•our financial results, including our ability to continue as a going concern, generate earnings and achieve and sustain profitability, which may vary significantly from forecasts and from period to period;

•the progress, timing and completion of our research, development and preclinical studies and clinical trials for our products and product candidates;

•the entry into definitive agreements with respect to the